ATE535521T1 - Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten - Google Patents

Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten

Info

Publication number
ATE535521T1
ATE535521T1 AT09726601T AT09726601T ATE535521T1 AT E535521 T1 ATE535521 T1 AT E535521T1 AT 09726601 T AT09726601 T AT 09726601T AT 09726601 T AT09726601 T AT 09726601T AT E535521 T1 ATE535521 T1 AT E535521T1
Authority
AT
Austria
Prior art keywords
pyrrolidine
hydroxymethyl
beta
receptor agonists
adrenergic receptor
Prior art date
Application number
AT09726601T
Other languages
English (en)
Inventor
Richard Berger
Lehua Chang
Scott Edmondson
Stephen Goble
Sookhee Ha
Nam Kar
Ihor Kopka
Bing Li
Gregori Morriello
Chris Moyes
Dong-Ming Shen
Liping Wang
Cheng Zhu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE535521T1 publication Critical patent/ATE535521T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
AT09726601T 2008-04-04 2009-04-02 Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten ATE535521T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12306308P 2008-04-04 2008-04-04
US20604309P 2009-01-27 2009-01-27
PCT/US2009/039253 WO2009124167A1 (en) 2008-04-04 2009-04-02 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
ATE535521T1 true ATE535521T1 (de) 2011-12-15

Family

ID=40671093

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09726601T ATE535521T1 (de) 2008-04-04 2009-04-02 Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten

Country Status (41)

Country Link
US (3) US8247415B2 (de)
EP (1) EP2276756B9 (de)
JP (3) JP4783867B2 (de)
KR (3) KR101331771B1 (de)
CN (2) CN102391255B (de)
AR (1) AR072043A1 (de)
AT (1) ATE535521T1 (de)
AU (1) AU2009231714B2 (de)
BR (1) BRPI0909768B1 (de)
CA (1) CA2719876C (de)
CL (1) CL2009000815A1 (de)
CO (1) CO6331440A2 (de)
CR (2) CR11751A (de)
CY (1) CY1112552T1 (de)
DO (2) DOP2010000294A (de)
EA (1) EA020135B1 (de)
EC (1) ECSP10010518A (de)
ES (1) ES2376278T3 (de)
FI (1) FIC20240046I1 (de)
FR (1) FR24C1051I2 (de)
GE (1) GEP20125666B (de)
HN (1) HN2010002030A (de)
HR (1) HRP20120129T2 (de)
IL (1) IL208215A (de)
MA (1) MA32257B1 (de)
ME (1) ME01988B (de)
MX (1) MX2010010929A (de)
NI (1) NI201000164A (de)
NL (1) NL301305I2 (de)
NO (1) NO2024055I1 (de)
NZ (1) NZ588266A (de)
PE (1) PE20091825A1 (de)
PL (1) PL2276756T3 (de)
PT (1) PT2276756E (de)
RS (1) RS52175B (de)
SG (1) SG188883A1 (de)
SI (1) SI2276756T1 (de)
SV (1) SV2010003687A (de)
TW (1) TWI378098B (de)
WO (2) WO2009124167A1 (de)
ZA (1) ZA201006720B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891872A (en) 1988-05-09 1990-01-09 Sussman Martin V Apparatus for incrementally drawing fibers
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
AU2010286694B2 (en) * 2009-08-27 2013-09-12 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
CA2774992A1 (en) * 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
JP5812500B2 (ja) * 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
EP2595483B1 (de) * 2010-07-23 2017-03-22 Merck Sharp & Dohme Corp. Neue, aus einem pyrrolidin abgeleitete beta-3-adrenerge rezeptoragonisten
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
SG187689A1 (en) * 2010-08-03 2013-03-28 Altherx Inc Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
GB2484713A (en) 2010-10-21 2012-04-25 Optovate Ltd Illumination apparatus
JP6042433B2 (ja) * 2011-08-11 2016-12-14 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ １，２，４−トリアゾリル置換されたケトエノール類
US9809536B2 (en) 2011-10-27 2017-11-07 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
US20150087832A1 (en) 2011-10-27 2015-03-26 Merck Sharp & Dohme, Corp. Process for making beta 3 agonists and intermediates
WO2013074650A1 (en) 2011-11-18 2013-05-23 Codexis, Inc. Biocatalysts for the preparation of hydroxy substituted carbamates
WO2013119910A1 (en) 2012-02-09 2013-08-15 Altherx, Inc. Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
JP2015178458A (ja) * 2012-07-25 2015-10-08 杏林製薬株式会社 ベンゼン環縮合含窒素５員複素環式化合物、またはその薬理学的に許容される塩
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
HRP20191546T1 (hr) 2013-03-15 2019-11-29 Merck Sharp & Dohme Postupak za pripravu beta 3 agonista i intermedijera
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
CN103760286A (zh) * 2014-01-14 2014-04-30 北京万全德众医药生物技术有限公司 一种用高效液相色谱法测定琥珀酸索非那新中间体光学纯度的方法
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
EP3226849A4 (de) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung von solabegron mit modifizierter freisetzung für symptome der unteren harnwege
MX2017009445A (es) 2015-01-20 2017-11-08 Merck Sharp & Dohme Inhibidores del factor xia.
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
US20170348263A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
GB201705365D0 (en) 2017-04-03 2017-05-17 Optovate Ltd Illumination apparatus
GB201705364D0 (en) 2017-04-03 2017-05-17 Optovate Ltd Illumination apparatus
EP3630783A4 (de) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillinbindende proteininhibitoren
JP7670461B2 (ja) 2017-06-06 2025-04-30 ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング 過活動膀胱の治療のためのビベグロンの投薬
US12102638B2 (en) 2017-06-06 2024-10-01 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201718307D0 (en) 2017-11-05 2017-12-20 Optovate Ltd Display apparatus
US11376253B2 (en) * 2017-12-21 2022-07-05 Kyorin Pharmaceutical Co., Ltd. Agent for treating nocturnal pollakiuria
GB201800574D0 (en) 2018-01-14 2018-02-28 Optovate Ltd Illumination apparatus
GB201803767D0 (en) 2018-03-09 2018-04-25 Optovate Ltd Illumination apparatus
GB201807747D0 (en) 2018-05-13 2018-06-27 Optovate Ltd Colour micro-LED display apparatus
CA3098536A1 (en) 2018-05-23 2019-11-28 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
SG11202103662VA (en) 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
CN109503500A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 一种2-(2-氧代吡嗪-1(2h)-基)乙酸的合成方法
CN109734712B (zh) * 2019-01-30 2020-10-20 广东东阳光药业有限公司 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
PH12021551975A1 (en) 2019-03-18 2022-07-04 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
KR102905477B1 (ko) 2019-07-02 2025-12-31 리얼디 스파크, 엘엘씨 지향성 디스플레이 장치
US11294233B2 (en) 2019-08-23 2022-04-05 ReaID Spark, LLC Directional illumination apparatus and privacy display
US11016341B2 (en) 2019-09-11 2021-05-25 Reald Spark, Llc Directional illumination apparatus and privacy display
EP4028805A4 (de) 2019-09-11 2023-10-18 RealD Spark, LLC Umschaltbare beleuchtungsvorrichtung und sichtschutzanzeige
WO2021067612A1 (en) 2019-10-03 2021-04-08 Reald Spark, Llc Illumination apparatus comprising passive optical nanostructures
US11162661B2 (en) 2019-10-03 2021-11-02 Reald Spark, Llc Illumination apparatus comprising passive optical nanostructures
EP4107580A4 (de) 2020-02-20 2024-03-20 RealD Spark, LLC Beleuchtungs- und anzeigevorrichtung
CA3189771A1 (en) * 2020-07-22 2022-01-27 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
KR20240110911A (ko) 2020-12-22 2024-07-16 유로반트 사이언시즈 게엠베하 과민성 방광을 치료하기 위한 비베그론을 사용하여 디곡신을 모니터링하는 방법
TW202245781A (zh) 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法
WO2022271582A1 (en) 2021-06-22 2022-12-29 Reald Spark, Llc Illumination apparatus
GB202113588D0 (en) 2021-09-23 2021-11-10 Atrogi Ab New compounds and methods
US12357655B2 (en) 2022-03-02 2025-07-15 Bonafide Health, Llc Polyglutamic acid compositions and methods of using
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
CN114920771A (zh) * 2022-05-13 2022-08-19 苏州虞美景盛新药开发有限公司 一种用于膀胱过度活动症的口服新药的中间体新合成工艺
US12048712B2 (en) 2022-10-18 2024-07-30 Bonafide Health, Llc Beta-adrenergic agonist and muscarinic antagonist compositions and methods of using
CN115850286B (zh) * 2022-12-05 2023-08-22 奥锐特药业(天津)有限公司 一种维贝格龙中间体及其制备方法
CN117756809A (zh) * 2023-12-21 2024-03-26 苏州莱克施德药业有限公司 (6s)4,6,7,8-四氢-4-氧代吡咯并[1,2-a]嘧啶-6-羧酸甲酯的合成方法
WO2025262600A1 (en) 2024-06-17 2025-12-26 Urovant Sciences Gmbh Crystalline form of vibegron hemihydrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
ZA200503510B (en) * 2002-11-07 2006-12-27 Yamanouchi Pharma Co Ltd Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
FR2874011B1 (fr) * 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3

Also Published As

Publication number Publication date
MA32257B1 (fr) 2011-04-01
IL208215A0 (en) 2010-12-30
CR20120282A (es) 2012-07-03
CN102056917B (zh) 2014-11-05
GEP20125666B (en) 2012-10-10
ECSP10010518A (es) 2010-11-30
FR24C1051I1 (fr) 2025-01-17
US8399480B2 (en) 2013-03-19
ME01988B (me) 2012-08-31
BRPI0909768A2 (pt) 2015-10-06
EP2276756A1 (de) 2011-01-26
WO2009124166A1 (en) 2009-10-08
RS52175B (sr) 2012-08-31
EP2276756B8 (de) 2012-04-11
DOP2013000267A (es) 2014-01-31
CY1112552T1 (el) 2016-02-10
CL2009000815A1 (es) 2009-08-21
TWI378098B (en) 2012-12-01
AU2009231714A1 (en) 2009-10-08
SG188883A1 (en) 2013-04-30
PE20091825A1 (es) 2009-12-04
WO2009124167A1 (en) 2009-10-08
JP4783867B2 (ja) 2011-09-28
KR20120118086A (ko) 2012-10-25
KR20120104257A (ko) 2012-09-20
DOP2010000294A (es) 2010-12-31
EA020135B1 (ru) 2014-08-29
US20110028481A1 (en) 2011-02-03
KR101331771B1 (ko) 2013-11-22
JP2011510023A (ja) 2011-03-31
EP2276756B9 (de) 2012-08-15
SV2010003687A (es) 2011-03-23
US8653260B2 (en) 2014-02-18
FR24C1051I2 (fr) 2026-01-16
ES2376278T3 (es) 2012-03-12
AU2009231714B2 (en) 2011-11-03
BRPI0909768B1 (pt) 2019-01-15
NL301305I2 (nl) 2024-12-30
KR101288798B1 (ko) 2013-07-23
SI2276756T1 (sl) 2012-04-30
JP2012020961A (ja) 2012-02-02
EP2276756B1 (de) 2011-11-30
CA2719876A1 (en) 2009-10-08
KR20100126860A (ko) 2010-12-02
CR11751A (es) 2010-11-22
CN102056917A (zh) 2011-05-11
PT2276756E (pt) 2012-02-03
HN2010002030A (es) 2012-08-13
HK1147099A1 (en) 2011-07-29
JP4783870B1 (ja) 2011-09-28
EA201071169A1 (ru) 2011-04-29
NZ588266A (en) 2011-11-25
ZA201006720B (en) 2011-05-25
CN102391255A (zh) 2012-03-28
NI201000164A (es) 2011-06-21
PL2276756T3 (pl) 2012-04-30
CA2719876C (en) 2013-10-01
HRP20120129T8 (en) 2012-04-30
JP2011201897A (ja) 2011-10-13
HRP20120129T1 (hr) 2012-03-31
MX2010010929A (es) 2010-11-12
US20090253705A1 (en) 2009-10-08
US20120258963A1 (en) 2012-10-11
CN102391255B (zh) 2014-07-09
TW200944521A (en) 2009-11-01
CO6331440A2 (es) 2011-10-20
FIC20240046I1 (fi) 2024-12-16
JP5432846B2 (ja) 2014-03-05
NO2024055I1 (no) 2024-12-12
US8247415B2 (en) 2012-08-21
IL208215A (en) 2014-04-30
HRP20120129T2 (hr) 2012-09-30
AR072043A1 (es) 2010-08-04

Similar Documents

Publication Publication Date Title
ATE535521T1 (de) Hydroxymethyl-pyrrolidine als beta-3-adrenerge rezeptoragonisten
LTPA2020513I1 (lt) S1P receptoriaus agonisto dozavimas
ATE524460T1 (de) Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
BRPI0806500A2 (pt) Agonistas gpcr de piperidina
ATE537157T1 (de) Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
ATE531710T1 (de) Piperidin-gpcr-agonisten
BRPI0921242A2 (pt) composições para tratamento bucal para sensibilidade.
EP2302180A4 (de) Baumaschine
BRPI0921815A2 (pt) compostos receptores de apj
EP2262891A4 (de) Extrazelluläre-matrix-zusammensetzungen
EP2490709A4 (de) Peptidische glp-2-agonisten
EP2303378A4 (de) Schnittstelle
EP2459581A4 (de) Leber x-rezeptor-agonisten
EP2350060A4 (de) Melanocortin-rezeptor-agonisten
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
EP2315564A4 (de) Wundverband
BRPI0907122A2 (pt) Piridoindóis (1-azinona) substituídos
BRPI0915781A2 (pt) oxazolopiridimas como agonista do receptor edg-1
BRPI0919135A2 (pt) compostos inéditos como ligantes do receptor canabinóide.
EP2317017A4 (de) Baumaschine
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
EP2427194A4 (de) Aus einem pyrrolidin abgeleitete beta-3-adrenerge rezeptoragonisten
DK2132185T3 (da) Pyrimidinyl-piperaziner nyttige som dopamin-D3/D2-receptorligander
BRPI0917563A2 (pt) porta-objeto